|
|
Dynavax
Technologies (DVAX)
Discover, Develop,
Commercialize
Website:
www.dynavax.com
DVAX
Investor Highlights
- Announced statistically
significant results from the primary endpoint analysis of a Phase 3
trial comparing HEPLISAV, its hepatitis B virus (HBV) vaccine, to
GlaxoSmithKline's Engerix-B vaccine in a difficult-to-immunize
population of older adults.
- Reported data from a Phase
2b study showing TOLAMBA(TM), the company's novel ragweed
investigational therapy, benefited treated patients, regardless of the
severity of their disease.
- Presented preclinical data
that shows its influenza (flu) vaccine can improve the immunogenicity of
standard flu vaccines. Dynavax said that the data from mouse and primate
models demonstrate that co-administration of Dynavax's flu vaccine with
standard vaccine enhances the immune response of the standard vaccine,
allows reduction of standard vaccine dosage, and provides extra layers
of protection that are not strain-dependent.
Overview
Dynavax Technologies Corporation discovers,
develops, and intends to commercialize innovative TLR9 agonist-based
products to treat and prevent allergies, infectious diseases, cancer, and
chronic inflammatory diseases using versatile, proprietary approaches that
alter immune system responses in highly specific ways. The Company's
agonists are based on immunostimulatory sequences, or ISS, which are short
DNA sequences that enhance the ability of the immune system to fight disease
and control chronic inflammation.
Dynavax’s pipeline includes: TOLAMBA(TM), a
ragweed allergy immunotherapeutic, for which a major safety and efficacy
trial (DARTT) is currently underway, and that is in a supportive clinical
trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine in
Phase 3; and a therapy for non-Hodgkins lymphoma in Phase 2. Its preclinical
asthma and COPD programs are partnered with AstraZeneca. Funding for the
company’s other preclinical programs in cancer, hepatitis B and hepatitis
C therapies, and for an influenza vaccine has been provided by Symphony
Dynamo, Inc. and NIH, and these programs represent future partnering
opportunities.
This is an abbreviated profile and we encourage readers
interested in learning more about Dynavax to visit the company website at
www.dynavax.com.
Recent
News and Press Releases
Dynavax's
HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in
Phase 3 Trial
Dynavax
Reports New TOLAMBA Data at ACAAI Meeting
Dynavax
Technologies Names Michael Ostrach VP, Chief Business Officer and General
Counsel
Dynavax
Announces Third Quarter 2006 Financial Results and Updates 2006 Financial
Guidance
Dynavax's
Universal Flu Vaccine Improves Response of Standard Flu Vaccines
For the latest Quote and News on
DVAX Click Here.
Three
Month Chart
Outlook
Dynavax Technologies
Corporation, a small-cap company in the health care sector, is expected to
outperform the market over the next six months with above average risk. Source
MSN
Contacts
Dynavax Technologies
2929 Seventh Street
Suite 100
Berkeley, CA 94710-2753
Phone: 510-848-5100
SEC Filings
DVAX filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of DVAX, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site.
SmallCapReview.com has not been compensated for its
efforts in presenting the Dynavax Technologies profile on its website
and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary
basis in the open market before, during or after the profiling period of
this report. Information presented on our web site and within our reports
contain "forward looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|